Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21 R110

Autor: Paul J. Hengeveld, Y. Emre Ertem, Julie M. N. Dubois, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Ludo M. Evers, Kim Heezen, P. Martijn Kolijn, Olaf R. F. Mook, M. Mahdi Motazacker, Kazem Nasserinejad, S. Kersting, Peter E. Westerweel, Carsten U. Niemann, Arnon P. Kater, Anton W. Langerak, Mark-David Levin

Publikováno v: Leukemia, 36(7), 1935-1938. Nature Publishing Group
Hengeveld, P J, Ertem, Y E, Dubois, J M N, Mellink, C H M, van der Kevie-Kersemaekers, A-M, Evers, L M, Heezen, K, Kolijn, P M, Mook, O R F, Motazacker, M M, Nasserinejad, K, Kersting, S, Westerweel, P E, Niemann, C U, Kater, A P, Langerak, A W & Levin, M-D 2022, ' Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110 ', Leukemia, vol. 36, no. 7, pp. 1935-1938 . https://doi.org/10.1038/s41375-022-01600-6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faddf632bed0aa0326c60d56e6fb24a1
https://pure.eur.nl/en/publications/cca58e3c-bfba-46df-b5e8-942d64040987